Wed 25 March 2026

Policy and Advocacy Impact March 2026

The National Health Reform Agreement 2026-2031 was finally published ahead of the 1 July 2026 start date, after announcements earlier in the year a deal had been struck between the Commonwealth and jurisdictions.

This comes after AdPha successfully got support and alignment on key recommendations for Pharmaceutical Reform Agreement arrangements in both the Mid-term NHRA Review and the PRA Review conducted by the Commonwealth.

These are now broadly reflected in the NHRA 2026-2031, with aims to develop a new multilateral PRA during NHRA 2026-2031 to be incorporated into the next one.

It also affirms consideration for interim bilateral PRAs with ACT and NSW, which have been an ongoing discussion in recent years.

This week, Prof Suzi Nielsen, and Rhu Patel from AdPha’s Policy and Advocacy team, will give evidence at the Senate Inquiry into Health impacts of alcohol and other drugs in Australia, advocating for and elevating the important clinical roles pharmacists have to support patients in AOD care beyond medicines supply.

Rhu and Suzi will appear at 10.30am, Friday 27 March, and you can watch on @AUSParliamentLive or ParlView.

The State of Pharmacy: Workforce Insights 2025 roadshow continued with a presentation at the ACT Allied Heath Forum.

The P&A team also made submissions on National Electronic Medication Chart Framework and Draft Requirements and TGA’s medicines labelling standards which are key to enabling closed loop medication management and electronic medication management